Affinage

VIM

Vimentin · UniProt P08670

Length
466 aa
Mass
53.7 kDa
Annotated
2026-06-11
100 papers in source corpus 7 papers cited in narrative 7 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Vimentin (VIM) is a type III intermediate filament protein that acts as a structural and signaling node in epithelial-mesenchymal transition (EMT), cell migration, and tissue remodeling, and its level is a frequent target of upstream transcriptional and post-transcriptional control (PMID:29123267, PMID:35443793). In cancer cells VIM drives a mesenchymal, migratory phenotype: this program is restrained when BPIFB1 physically binds VIM to attenuate VIM-induced EMT and suppress nasopharyngeal carcinoma migration and invasion (PMID:29123267), whereas FSTL1 binding to VIM promotes colorectal cancer migration, invasion, and cytoskeletal rearrangement through focal adhesion signaling (PMID:29844309). VIM abundance is controlled upstream by multiple regulators, including METTL3-mediated m6A modification that suppresses VIM in neurons downstream of EGR1, limiting hippocampal neuronal injury (PMID:37268752). Beyond its cancer/cytoskeletal roles, genetic deletion of VIM in mice causes failure of vascular remodeling and patent ductus arteriosus, placing VIM upstream of Jagged1/Notch3 signaling in ductal closure (PMID:35443793). VIM also undergoes citrullination during autophagy in synovial fibroblasts, and citrullinated VIM physically associates with MHC class II molecules, a mechanism linked to autoantigen presentation in rheumatoid arthritis (PMID:31486697).

Mechanistic history

Synthesis pass · year-by-year structured walk · 7 steps
  1. 2015 Low

    Established that VIM sits within a regulated EMT program rather than acting autonomously, by showing its expression is inversely coupled to the tumor suppressor WWOX and to the epithelial marker CDH1.

    Evidence Retroviral WWOX overexpression in endometrial cancer cells with western blotting and functional adhesion/migration assays

    PMID:25892250

    Open questions at the time
    • VIM regulation inferred from expression correlation, not a direct mechanistic link to WWOX
    • no demonstration that VIM is required for the WWOX migratory phenotype
  2. 2017 Medium

    Identified BPIFB1 as a direct VIM-binding partner that suppresses VIM-induced EMT, defining a protein-protein interaction that restrains the pro-migratory function of VIM.

    Evidence Co-immunoprecipitation/mass spectrometry and in vitro migration/invasion assays in nasopharyngeal carcinoma cells

    PMID:29123267

    Open questions at the time
    • no reconstitution or structural mapping of the interaction interface
    • single-lab finding without reciprocal validation in other tumor types
  3. 2018 Medium

    Showed that a different partner, FSTL1, binds VIM to promote migration and cytoskeletal rearrangement, establishing VIM as a bidirectional effector whose output depends on its interacting partner.

    Evidence Co-immunoprecipitation and migration/invasion assays in colorectal cancer cells, with focal adhesion pathway readouts

    PMID:29844309

    Open questions at the time
    • interaction not validated by reconstitution
    • molecular basis linking VIM-FSTL1 binding to focal adhesion activation not resolved
  4. 2019 Medium

    Linked a post-translational modification of VIM to immune function, demonstrating that autophagy-driven citrullination of VIM generates a form that physically associates with MHC class II, providing a mechanism for autoantigen presentation.

    Evidence Reciprocal Co-IP, proximity ligation assay, and ACPA-positive RA sera with autophagy inhibitor experiments in synovial fibroblasts

    PMID:31486697

    Open questions at the time
    • does not establish the citrullination sites or enzyme responsible
    • MHC class II association not shown to functionally drive T-cell activation in this study
  5. 2020 Low

    Placed VIM under post-transcriptional control by a ceRNA circuit, showing LINC01503 sponges miR-133a-5p to upregulate VIM and promote EMT.

    Evidence Luciferase reporter and RNA immunoprecipitation assays with knockdown in gastric cardia adenocarcinoma cells

    PMID:33200343

    Open questions at the time
    • VIM regulation is indirect via the lncRNA/miRNA axis
    • no direct study of VIM protein function in this context
  6. 2022 High

    Demonstrated an in vivo developmental requirement for VIM, showing that knockout causes failed vascular remodeling and patent ductus arteriosus, and genetically placed VIM upstream of Jagged1/Notch3 signaling.

    Evidence Vimentin knockout mouse, single-cell RNA-sequencing of the ductus arteriosus, immunohistochemistry, and epistasis with Jagged1-deleted mice

    PMID:35443793

    Open questions at the time
    • molecular mechanism by which a cytoskeletal protein controls Notch3 ligand signaling is not defined
    • cell-type-autonomous versus systemic contribution not dissected
  7. 2023 Medium

    Extended upstream regulation of VIM to the nervous system, showing EGR1-induced METTL3 deposits m6A on VIM to suppress its expression and limit neuronal injury, establishing VIM as a damage-promoting effector in epilepsy.

    Evidence VIM knockdown and EGR1/METTL3/m6A pathway assays in a kainic acid epilepsy model with immunofluorescence and western blotting

    PMID:37268752

    Open questions at the time
    • specific m6A sites on VIM mRNA not mapped
    • not independently replicated

Open questions

Synthesis pass · forward-looking unresolved questions
  • How VIM's cytoskeletal/filament structure mechanistically couples to its diverse partner-dependent signaling outputs (EMT regulation, Notch3 control, MHC class II presentation) remains unresolved.
  • no structural model linking partner binding to filament dynamics in the corpus
  • the unifying biochemical mechanism across cancer, vascular, immune, and neuronal contexts is not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 2 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005856 cytoskeleton 1
Pathway
R-HSA-1266738 Developmental Biology 1
Partners
BPIFB1FSTL1MHC CLASS II

Evidence

Reading pass · 7 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2017 BPIFB1 physically interacts with vimentin (VIM) in NPC cells, as demonstrated by co-immunoprecipitation coupled with mass spectrometry, and this interaction attenuates VIM-induced epithelial-mesenchymal transition, thereby inhibiting nasopharyngeal carcinoma cell migration and invasion. Co-immunoprecipitation with mass spectrometry, western blotting, immunofluorescence, in vitro migration/invasion assays British journal of cancer Medium 29123267
2018 FSTL1 interacts with vimentin (VIM) as identified by co-immunoprecipitation, and this interaction promotes colorectal cancer cell migration, invasion, and cytoskeletal rearrangement via activation of the focal adhesion signaling pathway. Co-immunoprecipitation to identify VIM as FSTL1-binding partner, functional assays (migration, invasion), western blotting Cell death & disease Medium 29844309
2019 Autophagy induction in synovial fibroblasts promotes citrullination of vimentin (VIM), generating citrullinated VIM (cVIM), and cVIM physically interacts with MHC class II molecules as demonstrated by co-immunoprecipitation and proximity ligation assay, suggesting a mechanism by which autophagy promotes autoantigen presentation in rheumatoid arthritis. Co-immunoprecipitation, proximity ligation assay, immunoblotting with ACPA-positive RA patient sera, autophagy inhibitor (3-MA) experiments Autophagy Medium 31486697
2015 WWOX expression in endometrial cancer cells inversely correlates with VIM protein expression and positively with CDH1, placing VIM downstream of WWOX in the regulation of EMT; WWOX overexpression suppressed mesenchymal markers including VIM while altering cell adhesion and migration. Retroviral WWOX overexpression in ECC1 cells, western blotting for VIM/CDH1/ZEB1/SNAI1 protein levels, RT-qPCR, functional assays (adhesion, migration, MMP activity), DNA microarray International journal of oncology Low 25892250
2022 Genetic deletion of vimentin (VIM) in mice results in failure to complete vascular remodeling and closure of the ductus arteriosus. Single-cell RNA-sequencing and transgenic mouse studies showed that vimentin-null mice phenocopy patent ductus arteriosus associated with Jagged1/Notch3 pathway disruption, placing VIM upstream of Notch3 signaling in ductal closure. Vimentin knockout mouse model, single-cell RNA-sequencing of ductus arteriosus at E18.5/P0.5/P5, immunohistochemistry, genetic epistasis with Jagged1-deleted mice Arteriosclerosis, thrombosis, and vascular biology High 35443793
2023 METTL3-mediated m6A modification downregulates VIM expression in neurons; EGR1 transcriptionally activates METTL3, which in turn suppresses VIM, reducing hippocampal neuron injury and apoptosis in an epilepsy model. Knockdown of VIM reduced neuronal injury and inflammatory response in vivo. Loss- and gain-of-function experiments (VIM knockdown), mechanistic assays linking EGR1 → METTL3 → VIM via m6A modification, in vivo kainic acid epilepsy model, immunofluorescence, western blotting Neurochemical research Medium 37268752
2020 LINC01503 functions as a competing endogenous RNA (ceRNA) by sponging miR-133a-5p to upregulate VIM expression, promoting epithelial-mesenchymal transition and progression in gastric cardia adenocarcinoma cells. Luciferase reporter assay, RNA immunoprecipitation (RIP) assay, qRT-PCR, gain-of-function (LINC01503 knockdown), western blotting for VIM and EMT markers Digestive diseases and sciences Low 33200343

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrobial agents and chemotherapy 461 10722487
2020 Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Frontiers in cellular and infection microbiology 295 32719751
2001 Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrobial agents and chemotherapy 202 11451678
2010 Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clinical cancer research : an official journal of the American Association for Cancer Research 150 20975101
2003 On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. The Journal of antimicrobial chemotherapy 143 12562689
2002 Molecular characterization of metallo-beta-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. The Journal of antimicrobial chemotherapy 129 12003980
2017 BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. British journal of cancer 79 29123267
2000 Purification and biochemical characterization of the VIM-1 metallo-beta-lactamase. Antimicrobial agents and chemotherapy 74 11036013
2006 Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. Journal of clinical microbiology 71 17021059
2018 FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway. Cell death & disease 68 29844309
2019 First Report of blaVIM-4- and mcr-9-Coharboring Enterobacter Species Isolated from a Pediatric Patient. mSphere 65 31511372
2008 Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrobial agents and chemotherapy 64 18644957
2012 VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerging infectious diseases 63 22840969
2012 bla(IMP) and bla(VIM) mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India. Journal of infection in developing countries 58 23277500
2013 Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. European journal of cancer (Oxford, England : 1990) 56 24100025
2017 High Prevalence of blaNDM-1, blaVIM, qacE, and qacEΔ1 Genes and Their Association with Decreased Susceptibility to Antibiotics and Common Hospital Biocides in Clinical Isolates of Acinetobacter baumannii. Microorganisms 54 28417918
2014 DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncology letters 53 25202404
2010 Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4. Antimicrobial agents and chemotherapy 53 21149620
2008 ORTH/VIM proteins that regulate DNA methylation are functional ubiquitin E3 ligases. The Plant journal : for cell and molecular biology 53 18643997
2017 VIM-1 carbapenemase-producing Escherichia coli isolated from retail seafood, Germany 2016. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 50 29090680
2010 Spread of plasmids containing the bla(VIM-1) and bla(CTX-M) genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. The Journal of antimicrobial chemotherapy 50 20089541
2009 Infections with VIM-1 metallo-{beta}-lactamase-producing enterobacter cloacae and their correlation with clinical outcome. Journal of clinical microbiology 48 19741074
2009 Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. Antimicrobial agents and chemotherapy 45 19901092
2013 High prevalence of VIM-4 and NDM-1 metallo-β-lactamase among carbapenem-resistant Enterobacteriaceae. Journal of medical microbiology 43 23639985
2020 Emergence of a Multidrug-Resistant Enterobacter hormaechei Clinical Isolate from Egypt Co-Harboring mcr-9 and blaVIM-4. Microorganisms 41 32325973
2020 Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. International journal of antimicrobial agents 41 32450200
2021 CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell biology and toxicology 39 34018092
2019 Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. Autophagy 38 31486697
2005 VIM-12, a novel plasmid-mediated metallo-beta-lactamase from Klebsiella pneumoniae that resembles a VIM-1/VIM-2 hybrid. Antimicrobial agents and chemotherapy 38 16304191
2018 Long noncoding RNA VIM-AS1 promotes colorectal cancer progression and metastasis by inducing EMT. European journal of cell biology 37 29656793
2015 Comparison of Verona Integron-Borne Metallo-β-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles. Antimicrobial agents and chemotherapy 37 26666919
2009 Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorganic & medicinal chemistry 36 19553129
2018 Crystal structures of VIM-1 complexes explain active site heterogeneity in VIM-class metallo-β-lactamases. The FEBS journal 35 30430727
2011 Structural and computational investigations of VIM-7: insights into the substrate specificity of vim metallo-β-lactamases. Journal of molecular biology 34 21645522
2020 First Genomic Characterization of blaVIM-1 and mcr-9-Coharbouring Enterobacter hormaechei Isolated from Food of Animal Origin. Pathogens (Basel, Switzerland) 33 32842587
2019 blaVIM- and blaOXA-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda. BMC infectious diseases 33 31619192
2014 Emergence of VIM-2 and IMP-15 carbapenemases and inactivation of oprD gene in carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Lebanon. Antimicrobial agents and chemotherapy 33 24913164
2020 Comprehensive exploration of the translocation, stability and substrate recognition requirements in VIM-2 lactamase. eLife 32 32510322
2018 Clinical significance of long noncoding RNA VIM-AS1 and CTBP1-AS2 expression in type 2 diabetes. Journal of cellular biochemistry 30 30506719
2007 Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 beta-lactamases. The Journal of antimicrobial chemotherapy 30 17540674
2016 VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey. Microbial drug resistance (Larchmont, N.Y.) 28 27326514
2023 In silico designing and immunoinformatics analysis of a novel peptide vaccine against metallo-beta-lactamase (VIM and IMP) variants. PloS one 27 37471423
2011 Epidemiology and genetics of VIM-type metallo-β-lactamases in Gram-negative bacilli. Future microbiology 27 21449842
2018 High Prevalence of VIM, KPC, and NDM Expression among Surgical Site Infection Pathogens in Patients Having Emergency Surgery. Surgical infections 25 29979638
2008 VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. Antimicrobial agents and chemotherapy 25 18519714
1990 Distribution of VIM-2 and SSEA-1 glycoconjugate epitopes among human leukocytes and leukemia cells. Leukemia research 25 1690317
2021 Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing Enterobacteriaceae Isolated from the Mohamed VI University Hospital in Marrakech, Morocco. Antibiotics (Basel, Switzerland) 24 33925772
2021 First report of a blaVIM-1 metallo-β-lactamase-possessing Klebsiella michiganensis. Journal of global antimicrobial resistance 24 33957287
2019 A Single Salt Bridge in VIM-20 Increases Protein Stability and Antibiotic Resistance under Low-Zinc Conditions. mBio 24 31744917
2018 Prevalence of VIM- and GIM-producing Acinetobacter baumannii from patients with severe urinary tract infection. Acta microbiologica et immunologica Hungarica 23 30111160
2016 Epidemiology and virulence of VIM-4 metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from burn patients in eastern Algeria. Burns : journal of the International Society for Burn Injuries 23 27156788
2015 The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer. International journal of oncology 23 25892250
2010 Analysis of a novel class 1 integron containing metallo-beta-lactamase gene VIM-2 in Pseudomonas aeruginosa. Journal of microbiology (Seoul, Korea) 23 20127470
2018 Identification of blaVIM-1 Gene in ST307 and ST661 Klebsiella pneumoniae Clones in Italy: Old Acquaintances for New Combinations. Microbial drug resistance (Larchmont, N.Y.) 22 30589602
2011 VIM and IMP metallo-β-lactamases and other extended-spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae from environmental samples in a Tunisian hospital. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 22 21917010
2020 Probing the mechanisms of inhibition for various inhibitors of metallo-β-lactamases VIM-2 and NDM-1. Journal of inorganic biochemistry 21 32622213
2020 lncRNA VIM‑AS1 promotes cell proliferation, metastasis and epithelial‑mesenchymal transition by activating the Wnt/β‑catenin pathway in gastric cancer. Molecular medicine reports 21 33173977
2019 Emergence of Carbapenem-Resistant Pseudomonas asiatica Producing NDM-1 and VIM-2 Metallo-β-Lactamases in Myanmar. Antimicrobial agents and chemotherapy 21 31138570
2015 Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases. The FEBS journal 21 25601024
2015 Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 21 26638216
2014 Microbiological and molecular detection of VIM-1 metallo beta lactamase-producing Acinetobacter baumannii. European review for medical and pharmacological sciences 21 24763874
2013 Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing β-lactamases in Pseudomonas aeruginosa in Turkey. Diagnostic microbiology and infectious disease 21 24428980
2014 Emergence of VIM-producing Aeromonas caviae in Israeli hospitals. The Journal of antimicrobial chemotherapy 20 24390932
2007 Characterization of In3Mor, a new integron carrying VIM-1 metallo-beta-lactamase and sat1 gene, from Morganella morganii. The Journal of antimicrobial chemotherapy 20 17341470
2021 Epidemic Territorial Spread of IncP-2-Type VIM-2 Carbapenemase-Encoding Megaplasmids in Nosocomial Pseudomonas aeruginosa Populations. Antimicrobial agents and chemotherapy 19 33526490
2021 Nosocomial outbreak of monoclonal VIM carbapenemase-producing Enterobacter cloacae complex in an intensive care unit during the COVID-19 pandemic: an integrated approach. The Journal of hospital infection 19 34861315
2021 Discovery of phyto-compounds as novel inhibitors against NDM-1 and VIM-1 protein through virtual screening and molecular modelling. Journal of biomolecular structure & dynamics 19 34961397
2023 Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1. Antimicrobial agents and chemotherapy 18 37195077
2021 Genomic Characterization of VIM and MCR Co-Producers: The First Two Clinical Cases, in Italy. Diagnostics (Basel, Switzerland) 18 33418979
2021 Emergence of ST39 carbapenem-resistant Klebsiella pneumoniae producing VIM-1 and KPC-2. Microbial pathogenesis 18 34954336
2015 Inhibiting the VIM-2 Metallo-β-Lactamase by Graphene Oxide and Carbon Nanotubes. ACS applied materials & interfaces 18 25897818
2023 Single-cell RNA sequencing reveals that VIM and IFITM3 are vital targets of Dengzhan Shengmai capsule to protect against cerebral ischemic injury. Journal of ethnopharmacology 17 37004745
2019 Long Noncoding RNA VIM Antisense RNA 1 (VIM-AS1) Plays an Important Role in Development of Preeclampsia by Regulation of Epithelial Mesenchymal Transition. Medical science monitor : international medical journal of experimental and clinical research 17 31685789
2014 VIM proteins regulate transcription exclusively through the MET1 cytosine methylation pathway. Epigenetics 17 24762702
2023 VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization. International journal of oncology 16 36734275
2023 Insight into phylogenomic bias of blaVIM-2 or blaNDM-1 dissemination amongst carbapenem-resistant Pseudomonas aeruginosa. International journal of antimicrobial agents 16 36924802
2023 EGR1-Driven METTL3 Activation Curtails VIM-Mediated Neuron Injury in Epilepsy. Neurochemical research 16 37268752
2021 The VIM-AS1/miR-655/ZEB1 axis modulates bladder cancer cell metastasis by regulating epithelial-mesenchymal transition. Cancer cell international 16 33902589
2019 Detection of VIM-1-Producing Enterobacter cloacae and Salmonella enterica Serovars Infantis and Goldcoast at a Breeding Pig Farm in Germany in 2017 and Their Molecular Relationship to Former VIM-1-Producing S. Infantis Isolates in German Livestock Production. mSphere 16 31189558
2013 Probe ligation and real-time detection of KPC, OXA-48, VIM, IMP, and NDM carbapenemase genes. Diagnostic microbiology and infectious disease 16 23791387
2020 Knockdown of long non-coding RNA VIM-AS1 inhibits glioma cell proliferation and migration, and increases the cell apoptosis via modulation of WEE1 targeted by miR-105-5p. European review for medical and pharmacological sciences 15 32633376
2013 Detection of NDM-2-producing Acinetobacter baumannii and VIM-producing Pseudomonas aeruginosa in Palestine. Journal of global antimicrobial resistance 15 27873597
2007 Molecular cloning and biochemical characterization of VIM-12, a novel hybrid VIM-1/VIM-2 metallo-beta-lactamase from a Klebsiella pneumoniae clinical isolate, reveal atypical substrate specificity. Biochemistry 15 17944487
2021 Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients. Cancer genetics 14 34922269
2020 Occurrence of intI1-associated VIM-5 carbapenemase and co-existence of all four classes of β-lactamase in carbapenem-resistant clinical Pseudomonas aeruginosa DMC-27b. The Journal of antimicrobial chemotherapy 14 31647552
2019 Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 14 31786880
2022 Occurrence of NDM-1, VIM-1, and OXA-10 Co-Producing Providencia rettgeri Clinical Isolate in China. Frontiers in cellular and infection microbiology 13 35047418
2020 Long non-coding RNA VIM Antisense RNA 1 (VIM-AS1) sponges microRNA-29 to participate in diabetic retinopathy. Acta diabetologica 13 32447557
2018 Examination of methylation changes of VIM, CXCR4, DOK7, and SPDEF genes in peripheral blood DNA in breast cancer patients. Indian journal of cancer 13 30829272
2012 Detection and characterization of VIM-31, a new variant of VIM-2 with Tyr224His and His252Arg mutations, in a clinical isolate of Enterobacter cloacae. Antimicrobial agents and chemotherapy 13 22391550
2022 Transcriptional Evaluation of the Ductus Arteriosus at the Single-Cell Level Uncovers a Requirement for Vim (Vimentin) for Complete Closure. Arteriosclerosis, thrombosis, and vascular biology 12 35443793
2018 Emergence of blaVEB and blaGES among VIM-producing Pseudomonas aeruginosa clinical isolates in Alexandria, Egypt. Acta microbiologica et immunologica Hungarica 12 30403360
2016 Dissemination of a Multidrug-Resistant VIM-1- and CMY-99-Producing Proteus mirabilis Clone in Bulgaria. Microbial drug resistance (Larchmont, N.Y.) 12 27341161
2014 Epidemiology of VIM-1-imipenem resistant Pseudomonas aeruginosa in Iran: A systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 12 25535506
2018 Characterisation of VIM-2-producing Pseudomonas aeruginosa isolates from lower tract respiratory infections in a Spanish hospital. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 11 29978304
2017 Novel class 1 Integrons and sequence types in VIM-2 and VIM-11-producing clinical strains of Enterobacter cloacae. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 11 28739428
2008 Characterisation of the metallo-beta-lactamase VIM-6 and its genetic support. International journal of antimicrobial agents 11 18757180
2024 DNA methylation analysis of the SDC2, SEPT9 and VIM genes in fecal DNA for colorectal cancer diagnosis. BMC cancer 10 39350171
2024 An outbreak of blaKPC-4- and blaVIM-1-producing Klebsiella pneumoniae and Klebsiella variicola at a single hospital in South Korea. Antimicrobial resistance and infection control 10 39394195
2020 Long Non-coding RNA LINC01503 Promotes Gastric Cardia Adenocarcinoma Progression via miR-133a-5p/VIM Axis and EMT Process. Digestive diseases and sciences 10 33200343

Missed literature

Know a paper Affinage missed for VIM? Flag it for the maintainers and the community.

No submissions yet.